By Fineline Cube METiS Therapeutics (HKG: 7666) announced on August 31, 2026 a partnership with Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276). Under the agreement, METiS’ proprietary AiTEM artificial intelligence formulation platform will be deployed locally at Hengrui Pharma to accelerate the efficiency of drug formulation development.
Deal Milestone
| Item | Detail |
|---|---|
| Party A | METiS Therapeutics (HKG: 7666) |
| Party B | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) |
| Agreement Type | Partnership — local platform deployment |
| Technology | AiTEM — proprietary AI formulation platform |
| Deployment Model | Local installation at Hengrui Pharma |
| Objective | Accelerate efficiency of drug formulation development |
| Announcement Date | 31 Aug 2026 |
Platform Profile — NanoForge
- Positioning: The world’s first AI‑driven nano‑delivery platform, self‑developed by METiS Therapeutics, and the technological foundation behind the AiTEM deployment
- Core Capabilities:
- World‑first “AI for Nano” de novo lipid generation algorithms
- Lipid language foundation model
- METiS AI agent
- High‑throughput closed‑loop wet‑and‑dry experimental iteration platform
- Strategic Role: NanoForge has become a key AI for Science infrastructure determining drug delivery capabilities
Data & Pipeline Milestones (as of May 2026)
| Metric | Scale |
|---|---|
| Accumulated lipid structures | Over 10 million |
| Experimental data points | 100,000+ |
| Pipelines advanced | More than 10 first‑in‑class or best‑in‑class programs |
| Targeted delivery breakthroughs | Progress across 8 major human organs and tissues |
Market Impact & Outlook
- AI Meets Big Pharma Formulation: Formulation development remains a rate‑limiting step for complex drugs — particularly lipid nanoparticle (LNP)–delivered modalities such as siRNA, mRNA, and gene therapies. Local deployment of AiTEM inside Hengrui embeds AI‑driven formulation directly into one of China’s largest pharmaceutical R&D engines.
- Data Moat: With over 10 million lipid structures and 100,000 experimental data points, NanoForge’s closed‑loop wet‑and‑dry iteration model compounds a proprietary dataset advantage that is difficult for competitors to replicate.
- Organ‑Targeted Delivery: Breakthrough progress in targeted delivery across 8 major human organs and tissues expands the addressable indications for nano‑formulated drugs beyond the liver‑dominant tropism of first‑generation LNPs.
- Validation for METiS: A partnership with Hengrui (SHA: 600276; HKG: 1276) — China’s leading innovative drugmaker — represents a landmark commercial endorsement of METiS’ AI for Science platform model.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding platform deployment, formulation development outcomes, and pipeline progress. Actual results may differ due to risks including technology integration, research outcomes, regulatory timelines, and competitive dynamics.-Fineline Info & Tech